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Introduction
Adherence to oral antipsychotic medication is known 
to be poor, with compliance rates estimated at 
around 40–50%.1–3 Furthermore, many clinicians 
are not aware of the extent of their own patients’ 
compliance with oral treatment.4,5 Antipsychotic 
long-acting injections (LAIs) offer some assurance 
of regular drug treatment and are associated with 
lower relapse rates and hospital admissions.3,6,7 
However, despite their known benefits, prescribing 
of LAIs remains low; prescribing rates in the UK 
are estimated to be around 30%.8,9
Various reasons have been proposed for the 
underuse of LAIs,10 including clinician reluc-
tance,11,12 assumed patient objection to LAIs,13 
prescribers’ suboptimal clinical knowledge and 
the limited availability of second generation 
(SGA) LAIs.14,15 The use of LAIs is considered 
by many to be coercive and stigmatizing.13
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Abstract
Background: We aimed to assess patients’ views about antipsychotic long-acting injections 
(LAIs).
Methods: We interviewed patients prescribed an antipsychotic (oral or LAI) in our community 
teams. In a subanalysis, responses were analysed for differences between patients currently 
receiving an LAI and those prescribed only oral medication.
Results: In total, 226 patients (57%) completed the study questionnaire. The majority agreed 
that LAIs ensured delivery of the right amount of medication and protection against hospital 
admissions (57% and 60%, respectively). A minority of participants were more concerned than 
not about the use of a needle (46%), pain from injection (48%) and the need to travel to receive 
the injection (34%). A majority expressed a preference for injection site (deltoid or gluteal) 
(65%) and clinic location (69%). A higher proportion of patients currently receiving an LAI 
compared with those prescribed oral medication thought an LAI was beneficial because this 
formulation obviated the need to: swallow tablets (63% versus 41%; p = 0.0013), remember 
to take tablets daily (75% versus 51%; p = 0.0004), remember tablets when away from home 
(72% versus 49%; p = 0008). Current LAI users were more likely than those on oral treatment 
to agree that LAIs keep patients out of hospital (76% versus 44%; p = 0.0001) and that the 
injection ensured delivery of the right amount of medication (71% versus 44%; p = 0.0002). 
Women were more likely than men to prefer administration by a clinician of the same gender 
(34% versus 12%; p = 0.0001).
Conclusions: In our study, a greater proportion of patients prescribed an LAI regarded LAIs as 
beneficial compared with those on oral medication.
Keywords: antipsychotic, depot, long-acting injection, patient survey
Received: 12 November 2018; revised manuscript accepted: 28 March 2019.
Correspondence to:  
Shubhra Mace  
Maudsley Hospital, 
Pharmacy Department, 
Denmark Hill, London SE5 
8AZ, UK 
Institute of Pharmaceutical 
Science, King’s College, 
London, 5th Floor, 
Franklin-Wilkins Building, 
150 Stamford Street, 
London SE1 9NH, UK 
Shubhra.mace@slam.
nhs.uk
Oscar Chak  
Sharanjeet Punny  
Daniel Sedough-Abbasian  
Maudsley Hospital, 
Pharmacy Department, 
Denmark Hill, London, UK
Chirag Vegad  
King’s College Hospital, 
Pharmacy Department, 
Denmark Hill, London, UK
David M. Taylor  
Maudsley Hospital, 
Pharmacy Department, 
Denmark Hill, London, UK
Institute of Pharmaceutical 
Science, King’s College, 
London, UK
860977 TPP0010.1177/2045125319860977Therapeutic Advances in PsychopharmacologyS Mace, O Chak
research-article20192019
Original Research
Therapeutic Advances in Psychopharmacology 9
2 journals.sagepub.com/home/tpp
Informal observations from our own unit suggest 
that patients prefer oral medication and that many 
are reluctant to consider an antipsychotic LAI. 
However, published data report high patient satis-
faction with LAIs.8,16–18 In this study, we aimed to 
assess patients’ views about antipsychotic LAIs, 
using a semi-structured questionnaire.
Methods
All patients in four of the Trust’s ‘promoting 
recovery’ community mental health teams were 
approached over a 4 week period in 2016 to com-
plete a semi-structured questionnaire about their 
views on antipsychotic LAIs. Patients in ‘promot-
ing recovery’ teams have an established diagnosis 
of a psychotic illness. The questionnaire asked 
patients to agree or disagree with certain state-
ments about LAIs. The statements included the 
supposed benefits of LAIs, for example, the con-
venience or otherwise of not having to take a tab-
let daily and aspects of LAIs which may be of 
concern to some patients, for example, pain from 
the injection procedure. For the purpose of this 
survey, differences between individual drugs 
(LAIs and oral) were not emphasized.
All patients attending appointments were 
approached by one of four dedicated pharmacy 
staff in the reception areas of the teams. Patients 
were informed about the purpose of the survey, 
that responses would be anonymized and that no 
patient identifiable data would to be collected or 
recorded. Patients were not selected in any way to 
complete the questionnaire and each patient had 
the opportunity to decline to participate. Patients 
who agreed to participate were asked if they were 
prescribed an antipsychotic medication. Any 
patient currently prescribed an antipsychotic and 
agreeing to take part was included in the survey. 
Pharmacy staff assisted patients in answering the 
questionnaire (they gave clarification to enable 
understanding of each question).
To maintain patient anonymity and to ensure 
that the study did not interfere with patients’ cur-
rent treatment plans we did not ask for any patient 
identifiable data, including details about patients’ 
current or previous treatment. The only patient 
data recorded were gender and whether or not the 
patient was currently receiving an LAI or oral 
antipsychotic. Other data on medication, diagno-
ses and duration of illness were not recorded. 
Patients did not receive any reimbursement or 
inducement for completing the questionnaire.
In a subanalysis, responses were analysed for dif-
ferences between patients currently receiving an 
LAI and those prescribed only oral medication.
The study was exempt from Research Ethics 
Committee approval and was approved by the 
trust drug and therapeutics committee. Patient 
consent was assumed for those who agreed to 
complete the questionnaire.
Statistical analysis
Binary responses from the two groups (LAI ver-
sus oral antipsychotic) were analysed using 
Fisher’s exact test. Responses from men and 
women were analysed for certain questions using 
Fisher’s exact test.
Results
Comparison between the responses from 
patients prescribed an LAI versus only oral 
medication
During the study period 396 patients were 
approached to complete the questionnaire, of 
which 170 declined to take part. In total, 226 
patients (57%) completed the questionnaire 
(Table 1, Table 2 and Figure 1). Of these, 110 
patients were prescribed an LAI and 116 patients 
an oral antipsychotic medication.
Comparison between the responses from men 
(n = 138) and women (n = 88)
Overall, there was no difference between men 
and women in their preference for the site of 
injection administration: 67% of men versus 63% 
of women expressed a preference for the injec-
tion site. Deltoid administration was preferred by 
33% of men versus 39% of women and gluteal 
administration was preferred by 34% of men ver-
sus 24% of women. The proportion of men and 
women expressing a preference for the gender of 
the person administering the injection is shown 
in Figure 2.
Unprovoked patient comments
During the course of the survey, patients informed 
us about their experiences, concerns and fears 
about LAIs. There were some common themes: 
patients of both sexes reported feeling embar-
rassed by the injection administration procedure. 
Women from certain cultures informed us that 
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injection administration is problematic for them 
because they are not permitted to expose parts of 
their body to men. Some patients were unsure 
about the competence of the healthcare profes-
sional to administer the injection, and some were 
concerned about contracting a blood-borne infec-
tion from the needle. In some cases, patients felt 
there was a lack of empathy and kindness amongst 
clinical staff during injection administration.
Discussion
The majority of patients who participated in our 
survey agreed with most of the statements in the 
questionnaire about the benefits of LAIs, and 
fewer patients were more concerned than not 
about aspects of the injection administration pro-
cedure, such as pain from the injection proce-
dure. The majority of patients expressed a 
preference for the site of injection administration 
(gluteal or deltoid) and the geographical location 
of the clinic where the injection is administered. 
Women were more likely to express a preference 
for the gender of the person administering the 
injection, and more women than men preferred 
administration by someone of the same gender.
The survey revealed some important differences 
between the opinions of patients currently pre-
scribed an LAI compared with those prescribed 
Table 1. Responses to survey questions.
Questions All patients (LAI and oral)
(n = 226)
 Yes No Don’t know
Do you consider the following aspects of an LAI 
beneficial?
 
There is no need to swallow tablets 117 (52%) 105 (46%) 4 (2%)
There is no need to remember to take tablets daily 142 (63%) 77 (34%) 7 (3%)
There is no need to take tablets when away from home 136 (60%) 82 (36%) 8 (4%)
Other people cannot see what medication the patient is 
taking
103 (45%) 117 (52%) 6 (3%)
Do you think having an LAI:  
Ensures patients receive the right amount of the 
medication?
129 (57%) 87 (39%) 10 (4%)
Helps to keep patients out of hospital for longer? 135 (60%) 79 (35%) 12 (5%)
Provides an opportunity for patients to have regular 
contact with a healthcare professional?
133 (59%) 85 (38%) 8 (3%)
Do any of the following aspects of an LAI concern you?  
The needle 105 (46%) 120 (53%) 1 (1%)
Pain from the injection 108 (48%) 117 (51%) 1 (1%)
Regular travel to clinic for injection administration 76 (34%) 146 (65%) 3 (1%)
Do you have a preference for the site of injection 
administration?
147 (65%) 27 (12%) 52 (23%)
Do you have a preference for the gender of the person 
administering the injection?
67 (30%) 147 (65%) 12 (5%)
Do you have a preference for the location of the clinic 
where the injection is administered?
156 (69%) 49 (22%) 21 (9%)
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only oral medication. A higher proportion of 
patients receiving an LAI agreed with the benefits 
of LAIs stated in the questionnaire. The differ-
ence was numerically but not statistically 
Table 2. Comparison between the responses from patients prescribed an LAI versus only oral medication.
Patients currently receiving an LAI  
(n = 110) 
Patients currently prescribed an 
oral antipsychotic
(n = 116)
p value 
(depot 
versus oral
agree)
 Yes No Don’t know Yes No Don’t know
Do any of the following aspects 
of an LAI concern you?
 
The needle 48 (44%) 62 (56%) 0 (0%) 57 (49%) 58 (50%) 1 (1%) 0.4231
Pain from the injection 53 (48%) 57 (52%) 1 (1%) 55 (47%) 60 (52%) 1 (1%) 1.0000
Regular travel to clinic for 
injection administration
30 (27%) 79 (72%) 1 (1%) 46 (40%) 67 (58%) 2 (%) 0.0476*
Do you have a preference 
for the site of injection 
administration?
82 (75%) 6 (5%) 22 (20%) 65 (56%) 21 (18%) 30 (26%) 0.0015*
Do you have a preference 
for the sex of the person 
administering the injection?
29 (26%) 79 (72%) 2 (2%) 38 (33%) 68 (59%) 10 (8%) 0.1851
Do you have a preference for 
the location of the clinic where 
the injection is administered?
83 (76%) 20 (18%) 7 (6%) 73 (63%) 29 (25%) 14 (12%) 0.1431
*Significant p values.
Figure 1. Proportion of patients who agreed with the following benefits of a long-acting injection (LAI).
Significant p values are shown in bold.
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significant for the response ‘other people cannot 
see what medication the patient is taking’. Fewer 
patients prescribed an LAI were concerned about 
having to travel to receive the injection. Patients 
prescribed an LAI were more likely to express a 
preference for the site of injection administration.
Previous studies have shown good patient satis-
faction with LAIs,16–18 and a better acceptance 
of the injection amongst current and previous 
recipients of LAIs compared with those who are 
LAI-naïve.4 Other surveys have shown that 
patients prefer the formulation of medication 
they are currently prescribed.8,19 Walburn and 
colleagues suggested that the inclusion in studies 
of patients taking oral medication could mini-
mize such survey bias.16 In this survey, we 
included responses from patients prescribed an 
LAI and oral medications.
Many clinicians consider LAIs to be stigmatizing 
and to be associated with more severe and fre-
quent adverse effects than oral medication.20 
There is still the view amongst some prescribers 
that LAIs should not be used in first episode 
patients,21,22 and that patients find LAIs less 
acceptable than oral medication.13 It is worth not-
ing that patients’ general views about medication 
may not correlate with their attitudes towards 
taking medication: in a study by Goldbeck and 
colleagues, more patients said they would, if given 
the choice, continue depot treatment compared 
with those who actually expressed a positive view 
of depots.23 In practice, LAIs tend to be 
prescribed for patients who are poorly compliant 
with oral medication. However, in our experi-
ence, they are rarely continued for those who fail 
to attend for regular injections and, thus, curi-
ously, LAIs tend to be prescribed for patients who 
agree to the treatment, suggesting some degree of 
patient acceptability.
Patient preferences
Perhaps the most informative aspect of this survey 
was one we had not anticipated. Many patients 
volunteered information about their preferences 
and concerns without being specifically asked. In 
practice, patients are often offered the choice of 
LAI but not usually choices about the practical 
aspects of injection administration. We suggest 
that clinicians should, as a matter of routine, con-
sider practical barriers to LAI initiation and con-
tinuation and aim to provide all patients the choice 
of gender of clinician administering the injection 
and the geographical location of the clinic, and, 
wherever possible, the site of injection administra-
tion (deltoid or gluteal). Patient concerns about 
clinician competence and the safety of the proce-
dure should be anticipated and addressed.
Limitations of the study
Our survey was anonymous and we were careful 
to not undermine the patient–prescriber relation-
ship or interfere with patients’ current treatment 
plans. For this reason, we felt unable to ask 
patients prescribed an LAI whether they were 
Figure 2. Proportion of men and women who expressed a preference for the gender of the person 
administering the injection.
Significant p values are shown in bold.
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happy to continue the injection or whether they 
would prefer to take oral medication. We were 
also not able to determine whether patients had 
previously been prescribed either an oral or LAI 
medication. For the purpose of the survey, LAIs 
were considered as a single group: individual dif-
ferences between LAIs such as loading regimen 
and injection frequency, were not emphasized. 
Questionnaires were completed only by patients 
who consented to participate in our survey. It is 
possible that the patients who declined to partici-
pate may be importantly different to those who 
participated in the survey. It is also possible that 
participants modified their answers to the ques-
tions in response to being observed.
Strengths of the study
Patients were aware that the responses to the 
questionnaires were anonymous and that profes-
sionals involved in their care would not be 
informed about any information provided. We 
believe therefore, that patients were able to be 
open and honest when answering the survey ques-
tions, without the fear of any consequences.
Conclusion
In our study, a greater proportion of patients 
agreed with the benefits of LAIs and fewer 
patients were concerns about the practical aspects 
of the injection procedure. Patients currently pre-
scribed an LAI were more likely to regard LAIs as 
beneficial compared with those on oral medica-
tion. There are important differences between the 
preferences of men and women for certain practi-
cal aspects of the injection procedure.
Key points
 • Clinicians should be aware that many 
patients express a positive view of LAIs.
 • Patients should be involved in the choice 
about practical aspects of LAI administra-
tion: Patients should be asked if they have a 
preference for the gender of the person 
administering the LAI, the site of injection 
administration (deltoid or gluteal) and the 
geographical location of the clinic where 
the LAI is administered.
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